Primary sources

What does my state say?

Pick your state for the pharmacy board, then read the federal baseline in clinic order: 503A lists, interim policy, PCAC, GLP-1 and Melanotan warnings, shortages, and DailyMed. Primary sources only.

Loading…

High-traffic boards clinics ask about first. Full A–Z board index is below.

The federal baseline, in reading order

13 primary pages. The first four take about thirty minutes and cover most of what a pharmacy or counsel will ask.

How to read these pages (7 min)
  1. 1
    FDA Human Drug Compounding Overview

    Defines the federal compounding frame clinics and pharmacies argue inside.

  2. 2
    FDA Section 503A Bulk Drug Substances Lists

    The starting map for whether a bulk peptide can even be nominated or listed for patient-specific compounding.

  3. 3
    FDA 503A Category 1 / 2 / 3 bulk substances list (PDF)

    The downloadable category list clinics and pharmacies argue from when someone claims a bulk peptide is “on the list.”

  4. 4
    Bulk substances that may present significant safety risks

    Names substances FDA associates with compounding safety concerns. Read the current page before building a menu.

  5. 5
    Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (PDF)

    Defines Category 1 enforcement discretion and what sits outside the interim policy after the January 2025 revision.

  6. 6
    FDA 503A bulk drug substance pathways (interim policy)

    Explains statutory pathways and interim Category 1 posture after the Jan 2025 policy revision.

  7. 7
    July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting

    Meeting page and materials for the 2026 peptide votes. Advisory recommendations are not final FDA decisions.

  8. 8
    FDA concerns with unapproved GLP-1 drugs used for weight loss

    Explains why compounded GLP-1 programs need tighter intake and syringe counseling.

  9. 9
    FDA Drug Shortages Database

    Shortage status changes what compounding pathways pharmacies will defend.

  10. 10
    FDA Unapproved Drugs Initiative

    Context for enforcement against products marketed for human use without approval.

  11. 11
    FDA warning on unapproved and potentially dangerous tanning products

    Primary citation when clinics ask whether Melanotan II belongs anywhere near a menu.

  12. 12
    FDA information on outsourcing facilities (503B)

    Baseline for office-use and larger-batch compounding outside patient-specific 503A.

  13. 13
    DailyMed labeled drug information

    Fast check that a “branded” peptide ask actually has a labeled finished drug (Wegovy, Forzinity, Scenesse, Victoza).

Indexes and supervision

All 51 pharmacy boards, A to Z

Expand

Sources in hand? See how clinics run the program.

Once counsel and your pharmacy agree on the menu, the PeptIQ.io provider console handles the rest: protocol templates, patient logging between visits, adherence per patient, and refill nudges.

Educational reference only, not legal, medical, or regulatory advice. PeptIQ.io does not sell, source, or dispense peptides. Your counsel, your pharmacy, and your state boards decide what applies to your clinic. Verify every source before you rely on it.